Lipton A - Search Results

1

Pathologic fractures correlate with reduced survival in patients with malignant bone disease.

Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Saad F, et al. Among authors: lipton a. Cancer. 2007 Oct 15;110(8):1860-7. doi: 10.1002/cncr.22991. Cancer. 2007. PMID: 17763372 Free article. Clinical Trial.

2

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE. Brown JE, et al. Among authors: lipton a. J Natl Cancer Inst. 2005 Jan 5;97(1):59-69. doi: 10.1093/jnci/dji002. J Natl Cancer Inst. 2005. PMID: 15632381

3

Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.

Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR. Cook RJ, et al. Among authors: lipton a. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3361-7. doi: 10.1158/1078-0432.CCR-06-0269. Clin Cancer Res. 2006. PMID: 16740758 Clinical Trial.

4

Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease.

Saad F, Lipton A. Saad F, et al. Among authors: lipton a. Semin Oncol. 2007 Dec;34(6 Suppl 4):S17-23. doi: 10.1053/j.seminoncol.2007.10.006. Semin Oncol. 2007. PMID: 18068486 Review.

5

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.

Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE. Hirsh V, et al. Among authors: lipton a. J Thorac Oncol. 2008 Mar;3(3):228-36. doi: 10.1097/JTO.0b013e3181651c0e. J Thorac Oncol. 2008. PMID: 18317064 Free article. Clinical Trial.

6

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.

Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE. Lipton A, et al. Cancer. 2008 Jul 1;113(1):193-201. doi: 10.1002/cncr.23529. Cancer. 2008. PMID: 18459173 Free article.

7

Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity.

Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE. Major PP, et al. Among authors: lipton a. BMC Cancer. 2009 Aug 6;9:272. doi: 10.1186/1471-2407-9-272. BMC Cancer. 2009. PMID: 19660124 Free PMC article. Clinical Trial.

8

SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.

Saad F, Lipton A. Saad F, et al. Among authors: lipton a. Cancer Treat Rev. 2010 Apr;36(2):177-84. doi: 10.1016/j.ctrv.2009.11.005. Epub 2009 Dec 16. Cancer Treat Rev. 2010. PMID: 20015594 Review.

9

Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.

Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE. Brown JE, et al. Among authors: lipton a. Breast Cancer Res Treat. 2010 Oct;123(3):767-79. doi: 10.1007/s10549-010-0981-1. Epub 2010 Jun 24. Breast Cancer Res Treat. 2010. PMID: 20574672

10

Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients.

Brown JE, Cook RJ, Lipton A, Coleman RE. Brown JE, et al. Among authors: lipton a. Clin Cancer Res. 2012 Nov 15;18(22):6348-55. doi: 10.1158/1078-0432.CCR-12-1397. Epub 2012 Sep 4. Clin Cancer Res. 2012. PMID: 22952345

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

513 results

Search Page

Filters